Press coverage about Adamis Pharmaceuticals (NASDAQ:ADMP) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.4702186407831 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Market Cap to Track (nasdaqjournal.com)
- Adamis Pharmaceuticals (ADMP) Downgraded by ValuEngine to Sell (americanbankingnews.com)
- Adamis Pharmaceuticals Corp (ADMP) Expected to Post Quarterly Sales of $3.06 Million (americanbankingnews.com)
- -$0.19 Earnings Per Share Expected for Adamis Pharmaceuticals Corp (ADMP) This Quarter (americanbankingnews.com)
- Adamis: Wait For It (seekingalpha.com)
A number of analysts have recently weighed in on the company. Zacks Investment Research cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 16th. Maxim Group set a $5.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 23rd. Raymond James Financial set a $7.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 23rd. Finally, B. Riley raised their price objective on Adamis Pharmaceuticals from $6.25 to $7.50 and gave the stock a “buy” rating in a research report on Friday, March 23rd. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $6.50.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.